Liao CJ, et al. - Researchers investigated the LEGFLOW OTW drug coated balloon (DCB; coated with paclitaxel) for its safety and efficacy in treating femoropopliteal artery disease vs standard percutaneous transluminal angioplasty (PTA) in a Chinese population. In this prospective single centre, single blinded randomised controlled trial (RCT), 60 patients (38 men; mean age 68.7 ± 8.8 years) were randomised (1:1) to the DCB (n = 30) or PTA group (n = 30). Outcomes suggest that superior treatment outcomes were achieved with DCB vs PTA, with remarkably higher patency and lower clinically driven target lesion revascularization (CD-TLR) rates. These results are in line with the findings from other former DCB trials and demonstrate LEGFLOW OTW DCB as safe and efficacious for treating femoropopliteal artery disease.